StockData
Jazz Pharmaceuticals plc logo

Jazz Pharmaceuticals plc (JAZZ) stock

JAZZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 7/30122% above fair value
$247.77+7.06 (+2.93%)

Close on Nov 18, 2026Market cap $16.08BP/E 80.7Yield –

Jazz Pharmaceuticals pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Jazz Pharmaceuticals's pe ratio was 17.0× on Nov 11, 2026, against 17.1× a year earlier. Over the last 5 years it ranged from 11.0× to 178.3×, with a median of 18.9×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202617.0×+1.7
2025Jul 31, 202515.3×−2.1
2024Dec 31, 202417.3×−160.9
2023Dec 29, 2023178.3×+38.2
2021Oct 29, 2021140.0×+88.0
2020Dec 31, 202052.1×+37.8
2019Dec 31, 201914.3×−0.4
2018Dec 31, 201814.7×−7.5
2017Dec 29, 201722.2×+3.5
2016Dec 30, 201618.7×−8.3
2015Dec 31, 201527.0×−353.8
2014Dec 31, 2014380.8×+359.4
2013Dec 31, 201321.4×−2.0
2012Dec 31, 201223.5×+9.0
2011Dec 30, 201114.5×–

More Jazz Pharmaceuticals figures

See a number that looks wrong?